NO963837D0 - Nye muteiner av IFN- - Google Patents

Nye muteiner av IFN-

Info

Publication number
NO963837D0
NO963837D0 NO963837A NO963837A NO963837D0 NO 963837 D0 NO963837 D0 NO 963837D0 NO 963837 A NO963837 A NO 963837A NO 963837 A NO963837 A NO 963837A NO 963837 D0 NO963837 D0 NO 963837D0
Authority
NO
Norway
Prior art keywords
ifn
beta
those
muteins
recombinant dna
Prior art date
Application number
NO963837A
Other languages
English (en)
Other versions
NO318989B1 (no
NO963837L (no
Inventor
Susan E Goelz
Richard L Cate
Pingchang E Chow
Blake R Pepinsky
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO963837D0 publication Critical patent/NO963837D0/no
Publication of NO963837L publication Critical patent/NO963837L/no
Publication of NO318989B1 publication Critical patent/NO318989B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Amplifiers (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
NO19963837A 1994-03-15 1996-09-13 Nye muteiner av IFN-beta NO318989B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/213,448 US5545723A (en) 1994-03-15 1994-03-15 Muteins of IFN-β
PCT/US1995/003206 WO1995025170A1 (en) 1994-03-15 1995-03-13 NOVEL MUTEINS OF IFN-$g(b)

Publications (3)

Publication Number Publication Date
NO963837D0 true NO963837D0 (no) 1996-09-13
NO963837L NO963837L (no) 1996-11-14
NO318989B1 NO318989B1 (no) 2005-05-30

Family

ID=22795174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19963837A NO318989B1 (no) 1994-03-15 1996-09-13 Nye muteiner av IFN-beta

Country Status (12)

Country Link
US (2) US5545723A (no)
EP (1) EP0750668B1 (no)
JP (2) JP3822903B2 (no)
AT (1) ATE414152T1 (no)
AU (1) AU695208B2 (no)
CA (1) CA2185352C (no)
DE (1) DE69535883D1 (no)
DK (1) DK0750668T3 (no)
FI (1) FI120356B (no)
NO (1) NO318989B1 (no)
NZ (2) NZ329970A (no)
WO (1) WO1995025170A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948358B2 (en) * 1996-12-24 2011-11-23 Biogen Idec MA Inc. Stable liquid interferon formulations
PT1121156E (pt) 1998-10-16 2006-05-31 Biogen Idec Inc Conjugados de polimeros de interferao-beta-1a e as suas utilizacoes
DE69931507T2 (de) * 1998-10-16 2007-01-11 Biogen Idec Ma Inc., Cambridge Interferon-beta fusionsproteine und deren verwendungen
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
ATE432288T1 (de) 2001-02-27 2009-06-15 Maxygen Aps Neue interferon-beta-ähnliche moleküle
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
EP1435979A4 (en) * 2001-09-18 2008-01-23 Novartis Vaccines & Diagnostic METHODS OF TREATING MULTIPLE SCLEROSIS
ZA200700168B (en) 2001-10-10 2010-02-24 Novo Nordisk As Remodeling and glycoconjugation of peptides
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
AU2003263552A1 (en) 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004028472A2 (en) * 2002-09-27 2004-04-08 Biogen Idec Ma Inc. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β
EP1581631A4 (en) * 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
NZ548255A (en) 2004-02-02 2010-10-29 Ambrx Inc Modified human interferon polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1885858A2 (en) * 2005-05-19 2008-02-13 Bayer Schering Pharma Aktiengesellschaft Treatment of disease using an improved regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
EP1891224A1 (en) * 2005-05-19 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Interferon-beta gene therapy using an improved, regulated expression system
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
PT1917276T (pt) * 2005-08-26 2018-06-11 Ares Trading Sa Processo para a preparação de interferão beta glicosilado
US20080038224A1 (en) * 2006-03-28 2008-02-14 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
WO2008134406A1 (en) * 2007-04-25 2008-11-06 The Board Of Trustees Of The Leland Stanford Junior University Ischemia-induced neovascularization is enhanced by hcns-sc transplantation
EP2076533B1 (en) * 2007-05-02 2014-10-08 Ambrx, Inc. Modified interferon beta polypeptides and their uses
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP2379711B8 (en) * 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2019073315A1 (en) 2017-10-09 2019-04-18 Mansour Poorebrahim ANALOGUE PEPTIDE OF INTERFERON-BETA

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR860001471B1 (ko) * 1980-04-03 1986-09-26 비오겐 엔. 브이 인체의 섬유아세포 인터페론(IFN-β)폴리펩티드의 제조방법
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4572798A (en) * 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4816440A (en) * 1985-09-26 1989-03-28 Cetus Corporation Stable formulation of biologically active proteins for parenteral injection
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL92124A (en) * 1988-10-28 1996-10-31 Sidney Pestka Recombinant proteins modified to contain post-phosphorylation that do not occur in nature
WO1993015609A1 (en) * 1992-02-05 1993-08-19 Thomas Jefferson University Interferon gene therapy for the treatment of vascular disorders

Also Published As

Publication number Publication date
JP3822903B2 (ja) 2006-09-20
ATE414152T1 (de) 2008-11-15
WO1995025170A1 (en) 1995-09-21
US5545723A (en) 1996-08-13
NZ283217A (en) 1998-05-27
NO318989B1 (no) 2005-05-30
DK0750668T3 (da) 2009-03-02
FI120356B (fi) 2009-09-30
AU695208B2 (en) 1998-08-06
AU2120295A (en) 1995-10-03
NZ329970A (en) 2000-01-28
MX9604073A (es) 1997-12-31
JP2006199711A (ja) 2006-08-03
DE69535883D1 (de) 2008-12-24
US6127332A (en) 2000-10-03
FI963630A (fi) 1996-09-13
FI963630A0 (fi) 1996-09-13
JPH10500563A (ja) 1998-01-20
EP0750668B1 (en) 2008-11-12
EP0750668A1 (en) 1997-01-02
CA2185352C (en) 2005-02-22
NO963837L (no) 1996-11-14
CA2185352A1 (en) 1995-09-21

Similar Documents

Publication Publication Date Title
NO963837L (no) Nye muteiner av IFN-
DK75694A (da) Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren
NO931141L (no) Tnf-muteiner
WO1995025170B1 (en) NOVEL MUTEINS OF IFN-$g(b)
EP0787802A3 (no)
RU95115239A (ru) Аналог эритропоэтина
ATE152172T1 (de) Herstellung eines rekombinanten menschlichen interleukin-1-hemmers
SE9004010D0 (sv) Viralt medel
WO2002074980A3 (en) Muteins of hypoxia inducible factor alpha and methods of use thereof
KR870004143A (ko) Dna서열, 재조합 dna분자 및 뮬레리안억제 물질류 폴리펩티드의 생산 방법
ATE380866T1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors,deren herstellung und verwendungen
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
EP1323824A3 (en) Use of human keratinocyte growth factor-2 for the preparation of pharmaceutical compositions
DE69233143D1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
DE69229862D1 (de) Cysteinfreie il-6 mutanten
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE100717T1 (de) Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons.
IT1262545B (it) Sistema di espressione per linee cellulari eucariotiche
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Goelz et al. Muteins of IFN-beta
GR3025841T3 (en) An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
Yamaguchi et al. A procedure for the purification of ferritin using Matrex Red A

Legal Events

Date Code Title Description
MK1K Patent expired